Exact Sciences' Shares Take a Hit Following Colorectal Cancer Dx Presentation
October 29, 2010
Exact Sciences' Shares Take a Hit Following Colorectal Cancer Dx Presentation
In results reported Thursday, the company said that its Cologuard test achieved of 64 percent sensitivity for pre-cancers and 85 percent for cancer and a specificity of 88 percent.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Transgenomic to Develop RAS Mutation Test with Amgen for Metastatic CRC Patients
May 15, 2013 / Pharmacogenomics Reporter - Data from Exact Sciences' Clinical Trial Sends Stock Plunging
April 18, 2013 / GenomeWeb Daily News - UK Study Suggests VEGF Splice Isoform Ratio Could Predict Colorectal Cancer Patients' Avastin Response
November 2, 2012 / Pharmacogenomics Reporter - Exact Sciences Posts Flat Q2 Revenues
July 25, 2012 / GenomeWeb Daily News - Exact Sciences Launches Colorectal Cancer Screening Study
July 12, 2011 / GenomeWeb Daily News